Author

G. Moureau

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 5 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Organism:mouse· 6 Research Focus:drug response / drug discovery· 4 Research Focus:host-pathogen & immune response· 4 Organism:human· 2 Research Focus:benchmarking· 1 Approach:biophysical modeling· 1 Research Focus:phylogenetics / evolution· 1

Frequent Co-Authors

A. Nougairede· 5 shared M. Cochin· 5 shared X. de Lamballerie· 5 shared F. Touret· 4 shared J.-S. Driouich· 4 shared C. Solas· 3 shared G. Piorkowski· 3 shared K. Barthelemy· 3 shared

Activity by Year

2018-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 44 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

A. Nougairede

Mutual co-authors in cluster

Author profile →

6 papers

Recent·Most cited

In vivo rescue of arboviruses directly from subgenomic DNA fragments

M. Cochin, J.-S. Driouich, G. Moureau, G. Piorkowski, X. N. de Lamballerie, A. Nougairede

The paper demonstrates an in vivo method to generate arboviruses from subgenomic DNA fragments, achieving 100% infection rate in mice with optimized electroporation parameters.

bioRxiv · Jan 17, 2024 · PreprintMicrobiology

Pre-clinical evaluation of antiviral activity of nitazoxanide against Sars-CoV-2

J.-S. Driouich, M. Cochin, F. Touret, P.-R. Petit, M. Gilles, G. Moureau, K. Barthelemy, C. Laprie, T. Wattanakul, P. Chotsiri, R. M. Hoglund, J. Tarning, F. Escudie, I. Scandale, E. Chatelain, , A. Nougairede

This study evaluates nitazoxanide's antiviral activity against SARS-CoV-2 in vitro and in vivo, finding that its standard dosage is ineffective due to insufficient drug concentration in target organs.

bioRxiv · Dec 17, 2021Pathology

Alpha variant versus D614G strain in the Syrian hamster model

M. Cochin, L. Luciani, F. Touret, J. S. Driouich, P.-R. Petit, G. Moureau, C. Baronti, C. Laprie, L. Thirion, P. Maes, R. Boudewijns, J. Neyts, X. de Lamballerie, A. Nougairede

This study compares the SARS-CoV-2 Alpha variant and G614 strain in Syrian hamsters, finding similar replication and disease outcomes but a slight fitness advantage for G614.

bioRxiv · Apr 19, 2021 · PreprintMicrobiology

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2

F. Touret, J.-S. Driouich, M. Cochin, P. R. Petit, M. Gilles, K. Barthelemy, G. Moureau, F.-X. MAHON, D. Malvy, C. Solas, X. de Lamballerie, A. Nougairede

This study evaluates Imatinib's antiviral potential against SARS-CoV-2 in vitro and in vivo, finding it ineffective in key models despite plasma and lung concentrations.

bioRxiv · Nov 17, 2020Microbiology

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model

J.-S. Driouich, M. Cochin, G. Lingas, G. Moureau, F. Touret, P.-R. Petit, G. Piorkowski, K. Barthelemy, B. Coutard, J. Guedj, X. de Lamballerie, C. Solas, A. Nougairede

This study evaluates favipiravir's antiviral efficacy against SARS-CoV-2 in a Syrian hamster model, showing dose-dependent reduction of viral titers and disease symptoms.

bioRxiv · Jul 7, 2020Microbiology

Exploratory re-encoding of Yellow Fever Virus genome: new insights for the design of live-attenuated viruses

R. Klitting, T. Riziki, G. Moureau, G. Piorkowski, E. A. Gould, X. de Lamballerie

This study re-encodes the Yellow Fever Virus genome with synonymous mutations to create attenuated strains, finding that certain mutations reduce virulence without significantly affecting replication fitness.

bioRxiv · May 30, 2018Microbiology